PerpEquities

Equity · Healthcare

Medline Inc. (MDLN) perpetual futures

MDLN perpetual futures on 1 crypto exchange – live perp price vs the stock, funding rate, open interest and where to trade MDLNUSDT.

Medline Inc. is a US-based manufacturer and distributor of medical and surgical products, serving hospitals, surgical centers, physician practices and nursing homes worldwide through its Medline Brand and Supply Chain Solutions divisions.

$37.550.0%NASDAQ closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

venue perp mark · MEXC (MDLN/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

1/1 live markets
Venues
1
Live markets
1/1
24h volume
$101.3K
Open interest
$38.7K
Best liquidity
$4.2K
MEXC
Tightest spread
+42.6 bps
MEXC
Highest volume
$101.3K
MEXC
Settlement mix
USDT · 1/1
Perp/spot vol.
0.00x
Spot volume $350.4M
OI / float
0.00%
Float $19.2B
Spot performance
1D-2.11%
5D-3.24%
1M+4.90%
6M-0.16%
YTD-11.81%
1Y-9.66%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
MEXCTradeMDLN/USDTTrading$37.55+21.9% APR
+0.020% every 8h
+42.6 bps$4.2K$101.3K$38.7KUSDT20x

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 1 venues absorb $10k

Too thin: MEXC

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

MDLN

Tightest spread

MDLN

Highest volume

MDLN

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-11-04 · next report 2027-02-24 · Updated 32m ago
All financials →

Valuation & key figures

Market cap
$32.5B
Updated 32m ago
Revenue
$30.7B
Trailing 12 months
Revenue growth
+10%
FY2026 consensus
Profit margin
1.8%
Net income / revenue, TTM
P/E
55.3×
Forward 24.2× (FY2026)
P/S
1.1×
Price / sales, TTM
Peer P/E
30.6×
Similar listed perps
EV / EBITDA
16.4×
TTM
Free cash flow
$1.9B
Trailing 12 months
Net income
$564M
Trailing 12 months
Revenue estimate
$31.4B
FY2026 consensus
Earnings
2027-02-24
Revenue est. $8.5B · Updated 32m ago
Dividend
–
No dividend
Revenue (TTM)$30.7B– vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)5.7%– vs a year agoOperating income $1.74B
Net income (TTM)$564M– vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$1.9B– vs a year agoCapex $486M
Diluted EPS (TTM)$0.67– vs a year agoSum of the last 4 quarters
Net cash-$8.97B+42.8% vs a year agoCash + short-term investments - debt
  • Last report (2026-11-04): revenue beat by 1.7%, EPS beat by 28.2%Revenue $7.86B vs $7.72B expected (+1.7%); EPS $0.44 vs $0.34 (+28.2%).
  • Revenue growth steady: 10.4% year on yearQ3 '26 revenue $7.86B, against an average of 11.2% over the four quarters before.
  • 55.8% of pre-tax profit is eaten by non-operating lossesPre-tax income $1.12B vs operating income $1.74B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.
  • Capex 1.6% of revenue$486M invested in the last 4 quarters (– on a year earlier). Free cash flow $1.9B = 336.0% of net income.

Revenue, operating income and growth

quarterly
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 324 lines Medline Inc. reported to the SEC

Next catalyst

Catalysts

Earnings
2027-02-24
Revenue est. $8.5B · Updated 32m ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20261.55$31.4B+10%13
FY 20271.57$34B+8%14
FY 20281.76$36.7B+8%8
FY 20292.02$39.5B+8%5
FY 20302.25$42.5B+8%5
Q1 20270.34$7.9B+7%11
Source: FMP · Consensus

Company events

6
2027-02-24EarningsActual - / Estimate 0.39-
2026-11-04EarningsActual 0.44 / Estimate 0.343Beat
2026-08-05EarningsActual 0.5 / Estimate 0.352Beat
2026-05-06EarningsActual 0.33 / Estimate 0.295Beat
2026-02-25EarningsActual 0.225 / Estimate 0.238Miss
2025-11-04EarningsActual 0.31 / Estimate --

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 21, 2026, 09:06 PM UTC

Company profile

Sector
Healthcare
Industry
Medical - Instruments & Supplies
Chief executive
James Boyle
Employees
45,000
IPO date
Dec 17, 2025
Country
US
Exchange
NASDAQ Global Select
Website
Altman Z-scorei2.18
Piotroski scorei8/9
Overall ratingiB
Owner earningsi$993.36M$0.75 per share

Rating factors

Return on equityi
3/5
Return on assetsi
4/5
Debt to equityi
1/5
Price to earningsi
1/5
Price to booki
3/5
Market cap history
$32.46B+8.1%Aug 2026 – Nov 2026
$28.01B$31.85B$35.68BHigh: $35.68B · 2026-11-09Low: $28.01B · 2026-09-21Latest: $32.46B · 2026-11-20Aug 2026Sep 2026Oct 2026Nov 2026
Latest: $32.46B · 2026-11-20High: $35.68B · 2026-11-09Low: $28.01B · 2026-09-21
Largest fund holders
FundWeightShares held
VTI0.03%14.3M
FCNKX0.28%13.3M
VO0.18%12.2M
VXF0.2%5.7M
VTV0.07%5.5M
FLBL0.59%4.5M
VWUAX0.29%3.8M
VOE0.29%3.6M
FLCNX0.31%3.4M
FSMAX0.21%2.1M
IWR0.13%1.9M
FNITX0.26%1.9M

Analyst track record

How the analysts covering MDLN have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings135136
Analysts2929
Buy / hold / sell124 / 11 / 0125 / 11 / 0
Upgrades / downgrades / initiations0 / 0 / 260 / 0 / 26
Price targets hit / missed5 / 115 (4%)5 / 116 (4%)
Avg. return after a rating (TipRanks)-19.6%-19.6%
Best / worst call+15.2% / -36.8%+15.2% / -36.8%

After buy calls on this stock: median 21-day move -0.2% vs S&P 500 -0.5% (n = 110)

Latest ratings

DateAnalystCallTarget
Nov 20, 2026Glen SantangeloBarclaysNov 20, 2026BuyMaintained$45.00↗
Nov 13, 2026Ivan FeinsethTigress FinancialNov 13, 2026BuyReiterated$55.00↗
Nov 12, 2026Lisa GillJ.P. MorganNov 12, 2026BuyMaintained$47.00↗
Nov 11, 2026Ryan HalstedRBC CapitalNov 11, 2026BuyReiterated$46.00↗
Nov 9, 2026Andrew ObinBank of America SecuritiesNov 9, 2026BuyMaintained–↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$35.00$40.00$45.00$50.00Dec 25 · Buy 0 · Hold 0 · Sell 0Dec 25Jan 26 · Buy 21 · Hold 4 · Sell 0Feb 26 · Buy 22 · Hold 4 · Sell 0Feb 26Mar 26 · Buy 22 · Hold 4 · Sell 0Apr 26 · Buy 22 · Hold 4 · Sell 0Apr 26May 26 · Buy 24 · Hold 4 · Sell 0Jun 26 · Buy 24 · Hold 4 · Sell 0Jun 26Jul 26 · Buy 23 · Hold 2 · Sell 0Aug 26 · Buy 23 · Hold 2 · Sell 0Aug 26Sep 26 · Buy 23 · Hold 2 · Sell 0Oct 26 · Buy 23 · Hold 2 · Sell 0Oct 26Nov 26 · Buy 20 · Hold 2 · Sell 0Jan 26 · avg. target $47.13Feb 26 · avg. target $51.96Mar 26 · avg. target $52.29Apr 26 · avg. target $52.29May 26 · avg. target $51.54Jun 26 · avg. target $51.00Jul 26 · avg. target $51.32Aug 26 · avg. target $47.09Sep 26 · avg. target $46.36Oct 26 · avg. target $46.14Nov 26 · avg. target $45.95Dec 25 · month-end close $42.00Jan 26 · month-end close $44.20Feb 26 · month-end close $47.51Mar 26 · month-end close $44.50Apr 26 · month-end close $44.47May 26 · month-end close $36.56Jun 26 · month-end close $39.44Jul 26 · month-end close $39.28Aug 26 · month-end close $35.03Sep 26 · month-end close $34.70Oct 26 · month-end close $32.12Nov 26 · month-end close $37.04

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 20, 2026 · 135 ratings

Frequently asked questions

Where can I trade MDLN perpetual futures?

Medline Inc. (MDLN) perpetual futures trade on one crypto venue: MEXC. PerpEquities shows its live price, funding rate, open interest and liquidity.

Can I trade MDLN around the clock?

Yes. Unlike the underlying stock, MDLN perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on MDLN perpetuals?

Right now the MDLN perp funding rate is +21.9% annualized (one venue). A positive rate means longs pay shorts. PerpEquities shows the live rate and its history.

How does the MDLN perp price compare to the Medline Inc. stock?

The venue-median MDLN perp mark is $37.6 versus a reference stock price of $37.6, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a MDLN perpetual future?

A MDLN perpetual is a derivative that tracks the price of Medline Inc. with no expiry date. It lets you take long or short exposure to Medline Inc. on crypto venues, around the clock.

What is MDLNUSDT perpetual?

MDLNUSDT is the symbol most crypto exchanges use for the Medline Inc. perpetual settled in USDT (Tether). It tracks the MDLN share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

MDLN perpetuals · perpequities.comMDLN perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/mdln-perp"><img src="https://perpequities.com/badge/mdln-perp.svg" width="240" height="64" alt="MDLN perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of MDLN perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for MDLN — one email every Sunday.

Watchlist and alerts

Price and funding alerts for MDLN, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X